Anti-Human p53R2 (NT)
| Code | Size | Price |
|---|
| LEI-P149-20ug | 20 ug | £199.00 |
Quantity:
| LEI-P149-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:P151
Long Description:
The p53 tumor-suppresspr gene integrates numerous signals that control cell life and death. Several novel molecules involved in p53 signaling, including p53R2 , Chk2 (2), p53AIP1 (3), Noxa (4), PIDD (5), and PID/MTA2 (6), were recently discovered. p53R2 is a p53 inducible gene that contains a p53 binding sequence and encodes a subunit of the enzyme ribonucleotide reductase (1,7). p53R2 is induced by the reagents, ultraviolet and g-irradiation that cause DNA damages. The product of p53R2 gene is directly involved in the p53 checkpoint for repair of damaged DNA. The isoform of the p53 family member p73 also induces p53R2 expression (8). p53R2 is an important target of p53 for tumour suppression.
Target:
p53R2
References
1. Tanaka, H. et al. (2000) Nature. 404:42-9. 2. Matsuoka, S. et al. (1998) Science. 282:1893-7. 3. Oda, E. et al. (2000) Science. 288(5468):1053-8. 4. Oda, K. et al. (2000) Cell 102(6):849-62.
Related Products
| Product Name | Product Code | Supplier | p53R2 (NT) Blocking Peptide | LEI-P151 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|